Skip to main content
. 2016 Jun 16;1(9):e87607. doi: 10.1172/jci.insight.87607

Figure 2. PRL3-zumab specifically blocks PRL-3+ (but not PRL-3–) orthotopic gastric tumors.

Figure 2

(A) Western blot for endogenous PRL-3 in 22 human gastric cancer (GC) cell lines. Tumorigenic PRL-3+ or PRL-3– cell lines selected for subsequent animal models are indicated with a red asterisk. Mr, relative molecular mass (kDa). (B) Outline of the experimental orthotopic GC model in BALB/c nude mice. (C) PRL3-zumab inhibits PRL-3+ SNU-484 orthotopic gastric tumor growth. Top panels: mouse appearance at the end of the experiment (day 28). Arrows indicate abdominal distention in untreated mice. Bottom panels: excised stomachs with tumor areas framed in black lines. Scale bar: 10 mm. (D) Mean gastric tumor volumes in untreated and treated groups at day 28. n = 8 per group; P = 0.01, t test; data represent mean ± SEM. (E) Kaplan-Meier survival analysis of untreated (red lines) and treated (black lines) groups of mice. n = 4 per group; P = 0.006, log-rank test.